Watson unveils deal to acquire Actavis
Watson Pharmaceuticals Inc. plans to buy Actavis Group for 4.25 billion euros ($5.6 billion). Announced late Wednesday, the deal comes after recent buzz of a potential Watson acquisition of Switzerland-based Actavis by industry analysts.